News for AptarGroup, Inc. (ATR)

PR NewswireVANCOUVER, BC, May 27, 2025 Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc.VANCOUVER, BC, May 27, 2025 /PRNewswire/ --

On May 20, 2025, Marc Prieur, Segment President at AptarGroup Inc (ATR), sold 6,000 shares of the company, according to a SEC Filing. Following this transaction

On May 16, 2025, Hedi Tlili, Segment President at AptarGroup Inc's branch, sold 3,614 shares of AptarGroup Inc (ATR). Following this transaction, the insider no

On May 7, 2025, Shiela Vinczeller, the Chief Human Resources Officer at AptarGroup Inc, sold 995 shares of the company. Following this transaction, the insider

On May 6, 2025, Wells Fargo analyst Gabe Hajde maintains the rating for AptarGroup (ATR) as "Overweight." The decision reflects a stable outlook for the company

Wells Fargo has increased its target price for AptarGroup (ATR) from $162 to $170, maintaining an Overweight rating on the stock. The decision follows a robust

\nAdjusted Earnings Per Share (EPS): $1.20, with a 5% increase over the prior year period when neutralizing for currency effects and tax.Reported Sales: Decrease

May 02, 2025 / 01:00PM GMTOperator Ladies and gentlemen, thank you for standing by. Welcome to Aptar's 2025 1st quarter results conference call. At this time, a

Discover AptarGroup's Q1 2025 earnings insights, showcasing Pharma growth, innovation-driven resilience, and a strong Q2 outlook.

AptarGroup, Inc. (NYSE:ATR) Q1 2025 Earnings Conference Call May 2, 2025 9:00 AM ETCompany ParticipantsMary Skafidas - Senior Vice President, Investor...

Aptar (ATR) announced its first-quarter revenue of $887 million, slightly falling short of the anticipated $898.64 million. Despite this, the company experience

AptarGroup, Inc. (AIT) anticipates its fourth quarter total sales to vary between a 1% decrease to a 3% increase. The company expects EBITDA margins to be withi

\nAptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announces the commencement of

\nAptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has achieved the Platinum level rati

AptarGroup is poised for growth in its Pharma and Closure segments, but challenges are expected in the Beauty segment. See why I rate ATR stock a buy.

AptarGroup shares lag the market and seem overpriced. With new data coming soon, read here to know why waiting to upgrade ATR stock might be the smart move.

AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has been named one of Barron's [url=

Summary AptarGroup Inc (ATR), a prominent player in drug and consumer product dosing, dispensing, and protection technologies, has been honored by the global en

AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has been recognized for its leadersh